Caribou Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Caribou Biosciences, Inc. (CRBU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.47 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.47M shares, a 4.11% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 47.50K shares, a 27.09% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.23M shares, a 214.94% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.65M shares, a 29.27% increase from fiscal 2024.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.59M shares, a 1.96% increase from fiscal 2023.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.52M shares, a 150.07% increase from fiscal 2022.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.41M shares, a 71.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 3.47M shares 10-Q · filed 2026-08-13 | 3.52M shares derived: sum of 3 quarters · filed 2026-08-13 | 4.75M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 3.47M shares 10-Q · filed 2026-05-07 | 3.52M shares derived: sum of 2 quarters · filed 2026-05-07 | 4.75M shares derived: sum of 3 quarters · filed 2026-05-07 | 4.78M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 47.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 1.28M shares derived: sum of 2 quarters · filed 2026-03-05 | 1.31M shares derived: sum of 3 quarters · filed 2026-03-05 | 4.65M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 1.23M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.26M shares derived: sum of 2 quarters · filed 2025-11-12 | 4.60M shares 10-Q · filed 2025-11-12 | 4.66M shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-06-30 | 29.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 3.37M shares 10-Q · filed 2025-08-12 | 3.43M shares derived: sum of 3 quarters · filed 2026-03-05 | 3.82M shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-03-31 | 3.34M shares 10-Q · filed 2025-05-08 | 3.40M shares derived: sum of 2 quarters · filed 2026-03-05 | 3.79M shares derived: sum of 3 quarters · filed 2026-03-05 | 4.02M shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | 65.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 456.68K shares derived: sum of 2 quarters · filed 2026-03-05 | 680.13K shares derived: sum of 3 quarters · filed 2026-03-05 | 3.59M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 391.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 614.98K shares derived: sum of 2 quarters · filed 2024-11-06 | 3.53M shares 10-Q · filed 2024-11-06 | 3.65M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | 223.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 3.14M shares 10-Q · filed 2024-08-06 | 3.25M shares derived: sum of 3 quarters · filed 2025-03-10 | 3.64M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | 2.91M shares 10-Q · filed 2024-05-07 | 3.03M shares derived: sum of 2 quarters · filed 2025-03-10 | 3.42M shares derived: sum of 3 quarters · filed 2025-03-10 | 3.90M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | 117.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 501.91K shares derived: sum of 2 quarters · filed 2025-03-10 | 988.28K shares derived: sum of 3 quarters · filed 2025-03-10 | 3.52M shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 384.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 870.46K shares derived: sum of 2 quarters · filed 2023-11-07 | 3.41M shares 10-Q · filed 2023-11-07 | 3.61M shares derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-06-30 | 486.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 3.02M shares 10-Q · filed 2023-08-08 | 3.23M shares derived: sum of 3 quarters · filed 2024-03-11 | 3.60M shares derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-03-31 | 2.54M shares 10-Q · filed 2023-05-09 | 2.74M shares derived: sum of 2 quarters · filed 2024-03-11 | 3.11M shares derived: sum of 3 quarters · filed 2024-03-11 | 3.61M shares derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-12-31 | 202.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 575.33K shares derived: sum of 2 quarters · filed 2024-03-11 | 1.07M shares derived: sum of 3 quarters · filed 2024-03-11 | 1.41M shares 10-K · filed 2024-03-11 |
| 2022-09-30 | 372.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 867.72K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.21M shares 10-Q · filed 2022-11-08 | 3.26M shares derived: sum of 4 quarters · filed 2023-03-09 |
| 2022-06-30 | 495.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 834.15K shares 10-Q · filed 2022-08-09 | 2.89M shares derived: sum of 3 quarters · filed 2023-03-09 | |
| 2022-03-31 | 339.03K shares 10-Q · filed 2022-05-09 | 2.39M shares derived: sum of 2 quarters · filed 2023-03-09 | ||
| 2021-12-31 | 2.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 4.86M shares 10-K · filed 2023-03-09 | ||
| 2021-09-30 | 2.81M shares 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | 896.83K shares 10-Q · filed 2021-09-02 | 2.46M shares derived: sum of 2 quarters · filed 2021-09-02 | ||
| 2021-03-31 | 1.56M shares 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |